Inhibition of tumor growth by U0126 is associated with induction of interferon‐γ production. Issue 4 (28th June 2014)
- Record Type:
- Journal Article
- Title:
- Inhibition of tumor growth by U0126 is associated with induction of interferon‐γ production. Issue 4 (28th June 2014)
- Main Title:
- Inhibition of tumor growth by U0126 is associated with induction of interferon‐γ production
- Authors:
- Ma, Xingzhe
Wang, Qixue
Liu, Ying
Chen, Yuanli
Zhang, Ling
Jiang, Meixiu
Li, Xiaoju
Xiang, Rong
Miao, Robert Q.
Duan, Yajun
Han, Jihong - Abstract:
- <abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Several MEK1/2 inhibitors have been in clinical trial evaluation for cancer treatment. Interferon‐γ (IFN‐γ) is a cytokine with multiple biological functions including antitumor activity. Expression of IFN‐γ can be induced by liver X receptor (LXR), a ligand‐activated transcription factor. However, it remains unknown if the anti‐cancer action of MEK1/2 inhibitors is completed, at least in part, by activating IFN‐γ expression. In this study, we determined that U0126, a MEK1/2 inhibitor, increased tumor‐free and survival rates and decreased growth of inoculated Lewis lung carcinomas in wild type mice. However, the protective effects were substantially attenuated in IFN‐γ deficient (IFN‐γ<sup>−/−</sup>) mice. At cellular and molecular levels, MEK1/2 inhibitors increased IFN‐γ protein and mRNA expression and activated natural IFN‐γ promoter but not the IFN‐γ promoters with mutations of the LXR responsive elements (LXREs). MEK1/2 inhibitors also enhanced formation of the LXRE‐nuclear protein complexes by inducing LXR expression and nuclear translocation. Similarly, MEK1/2 siRNA inhibited phosphorylation of ERK1/2 by MEK1/2 while activated IFN‐γ expression. In contrast, inhibition of LXR expression by siRNA blocked MEK1/2 inhibitors‐induced IFN‐γ expression. U0126 also inhibited chemicals‐induced pulmonary carcinomas, which was associated with increased IFN‐γ expression in the lung. Taken<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Several MEK1/2 inhibitors have been in clinical trial evaluation for cancer treatment. Interferon‐γ (IFN‐γ) is a cytokine with multiple biological functions including antitumor activity. Expression of IFN‐γ can be induced by liver X receptor (LXR), a ligand‐activated transcription factor. However, it remains unknown if the anti‐cancer action of MEK1/2 inhibitors is completed, at least in part, by activating IFN‐γ expression. In this study, we determined that U0126, a MEK1/2 inhibitor, increased tumor‐free and survival rates and decreased growth of inoculated Lewis lung carcinomas in wild type mice. However, the protective effects were substantially attenuated in IFN‐γ deficient (IFN‐γ<sup>−/−</sup>) mice. At cellular and molecular levels, MEK1/2 inhibitors increased IFN‐γ protein and mRNA expression and activated natural IFN‐γ promoter but not the IFN‐γ promoters with mutations of the LXR responsive elements (LXREs). MEK1/2 inhibitors also enhanced formation of the LXRE‐nuclear protein complexes by inducing LXR expression and nuclear translocation. Similarly, MEK1/2 siRNA inhibited phosphorylation of ERK1/2 by MEK1/2 while activated IFN‐γ expression. In contrast, inhibition of LXR expression by siRNA blocked MEK1/2 inhibitors‐induced IFN‐γ expression. U0126 also inhibited chemicals‐induced pulmonary carcinomas, which was associated with increased IFN‐γ expression in the lung. Taken together, our study suggests that MEK1/2 inhibitors induce IFN‐γ production in an LXR‐dependent manner and the induction of IFN‐γ expression can partially contribute to the anti‐tumorigenic properties of U0126.</p> </abstract> … (more)
- Is Part Of:
- International journal of cancer. Volume 136:Issue 4(2015:Feb. 15)
- Journal:
- International journal of cancer
- Issue:
- Volume 136:Issue 4(2015:Feb. 15)
- Issue Display:
- Volume 136, Issue 4 (2015)
- Year:
- 2015
- Volume:
- 136
- Issue:
- 4
- Issue Sort Value:
- 2015-0136-0004-0000
- Page Start:
- 771
- Page End:
- 783
- Publication Date:
- 2014-06-28
- Subjects:
- Cancer -- Periodicals
Cancer -- Prevention -- Periodicals
616.994 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-0215 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/ijc.29038 ↗
- Languages:
- English
- ISSNs:
- 0020-7136
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.156000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3497.xml